Highlights
MWC-China collaboration celebrates anti-cancer drug clinical trials
A longstanding relationship between MWC and Chinese researchers is celebrating its first clinical candidate undergoing Phase 1 trials. LX-132 targets many different types of cancer
read the full story
Clinical trials for anti-cancer agent Tarloxotinib
Maurice Wilkins Centre has supported the Tarloxotinib drug development programme over many years. Now, the Phase II clinical stage anti-cancer agent has been acquired by Convert Ph
read the full story
New anti-viral based therapies for Covid-19: Protease inhibitors
Researchers at MWC are looking to develop novel inhibitors for SARS-CoV-2 Mpro by leveraging expertise within MWC’s Infectious Disease network for anti-viral drug development.
read the full story
TamoRx – a greater hope for a fighting chance
A spin out company focussed on developing immunotherapy medicines based on MWC research and facilities is providing hope for novel treatments to combat advanced metastatic cancer.
read the full story
New Otago biotech startup targets cancer
Amaroq Therapeutics, a new biotech startup company with the goal of developing targeted drugs for cancer, has been awarded significant investment funds in 2021.
read the full story
Exciting building blocks unlock peptide potential
Coined ‘bacterial super villains’, the World Health Organisation has a list of ‘priority pathogens’ which have developed resistance to most drugs. With the rise of these supe
read the full story
Nationwide research flagship takes fight to global viral threats
A growing network of Maurice Wilkins Centre investigators around New Zealand are collaborating on research to tackle important viral infectious diseases.
read the full story
Turning the tables on cancer
Tumours often contain areas with less oxygen than is found in normal tissues. These areas are less vulnerable to many forms of cancer therapy and often drive development of a more
read the full story